Safety Monitoring Committee Meeting Positive for Nymox Pivotal Phase 3 NX-1207 Trials

Nymox Pharmaceutical Corporation NYMX provided a further update today on the Company's ongoing Phase 3 trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The Safety Monitoring Committee meeting of May 3, 2011 found no significant safety concerns to date for the two pivotal U.S. trials being conducted at over 70 urology clinical research sites across the U.S.